GlassScriptPhysician profile
Steve N Dong
NPI 1760666499
$40,396.20
in general payments reported to CMS, 2019-2025
38 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,658 · 2020: $1,779 · 2021: $1,320 · 2022: $1,437 · 2023: $6,405 · 2024: $10K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $28K · Food and Beverage: $5,226 · Travel and Lodging: $853 · Gift: $22.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $28,099.99 |
| Food and Beverage | $5,225.93 |
| Travel and Lodging | $852.70 |
| Gift | $22.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $31,150.49 | 2019-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Biotissue Holdings INC. | $1,132.19 | 2021-2024 | |
| Dendreon Pharmaceuticals LLC | $1,107.74 | 2019-2025 | Provenge |
| Abbvie INC. | $948.12 | 2019-2025 | Lupron Depot |
| Janssen Biotech, INC. | $868.13 | 2019-2025 | Erleada, Akeega, Balversa |
| Neotract INC. | $812.17 | 2020 | |
| Astellas Pharma US INC | $603.40 | 2019-2024 | Xtandi |
| Tolmar Pharmaceuticals, INC. | $492.68 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $381.00 | 2019-2025 | |
| Tolmar, INC. | $352.34 | 2023-2025 | Eligard |
| Pfizer INC. | $338.18 | 2019-2025 | |
| Boston Scientific Corporation | $326.91 | 2019-2024 | Upsylon |
| Sumitomo Pharma America, INC. | $288.41 | 2023-2025 | Orgovyx, Gemtesa |
| Urogen Pharma, INC. | $236.45 | 2022-2025 | |
| Coloplast Corp | $171.91 | 2019-2023 | Speedicath |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $155.62 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $116.01 | 2020-2024 | Keytruda, Welireg, Lynparza |
| Teleflex LLC | $101.14 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $85.60 | 2019-2025 | Adstiladrin |
| Agiliti Health, INC. | $84.89 | 2019 | |
| Olympus America INC. | $82.39 | 2019 | |
| Novartis Pharmaceuticals Corporation | $74.48 | 2024-2025 | |
| Urovant Sciences INC | $68.39 | 2022 | |
| Baxter Healthcare | $63.67 | 2020 | |
| Blue Earth Diagnostics | $53.05 | 2019 | |
| Foundation Medicine, INC. | $46.07 | 2020-2021 | |
| Myriad Genetic Laboratories, INC. | $44.71 | 2022-2023 | Prolaris |
| Immunitybio, INC. | $40.67 | 2025 | |
| Convatec INC. | $32.31 | 2025 | |
| Integra Lifesciences Corporation | $22.94 | 2023 | Biodoptix, Biodfactor, Biodrestore |
| Otsuka America Pharmaceutical, INC. | $21.81 | 2019 | |
| Antares Pharma, INC. | $18.35 | 2019 | |
| Mimedx Group, INC. | $15.83 | 2025 | |
| Amgen INC. | $14.96 | 2020 | |
| Abc Home Medical Supply, INC. | $14.46 | 2022 | |
| Hollister Incorporated | $14.35 | 2019 | |
| Ethicon US, LLC | $11.74 | 2020 | |
| Travere Therapeutics, INC. | $2.64 | 2020-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Dong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.